Pelletier EM - Search Results

1

A pooled analysis of exenatide use and risk of acute pancreatitis.

Dore DD, Hussein M, Hoffman C, Pelletier EM, Smith DB, Seeger JD. Dore DD, et al. Among authors: pelletier em. Curr Med Res Opin. 2013 Dec;29(12):1577-86. doi: 10.1185/03007995.2013.838550. Epub 2013 Sep 13. Curr Med Res Opin. 2013. PMID: 23981106

2

Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study.

Wenten M, Gaebler JA, Hussein M, Pelletier EM, Smith DB, Girase P, Noel RA, Braun DK, Bloomgren GL. Wenten M, et al. Among authors: pelletier em. Diabet Med. 2012 Nov;29(11):1412-8. doi: 10.1111/j.1464-5491.2012.03652.x. Diabet Med. 2012. PMID: 22416857 Free PMC article.

3

Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database.

Best JH, Hoogwerf BJ, Herman WH, Pelletier EM, Smith DB, Wenten M, Hussein MA. Best JH, et al. Among authors: pelletier em. Diabetes Care. 2011 Jan;34(1):90-5. doi: 10.2337/dc10-1393. Epub 2010 Oct 7. Diabetes Care. 2011. PMID: 20929995 Free PMC article.

4

Patient out-of-pocket payments for oral oncolytics: results from a 2009 US claims data analysis.

Raborn ML, Pelletier EM, Smith DB, Reyes CM. Raborn ML, et al. Among authors: pelletier em. Am J Manag Care. 2012 May;18(5 Spec No. 2):SP57-64. Am J Manag Care. 2012. PMID: 22693982 Free article.

5

Patient Out-of-Pocket Payments for Oral Oncolytics: Results From a 2009 US Claims Data Analysis.

Raborn ML, Pelletier EM, Smith DB, Reyes CM. Raborn ML, et al. Among authors: pelletier em. J Oncol Pract. 2012 May;8(3 Suppl):9s-15s. doi: 10.1200/JOP.2011.000516. J Oncol Pract. 2012. PMID: 22942827 Free PMC article.

6

Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis.

Pelletier EM, Pawaskar M, Smith PJ, Best JH, Chapman RH. Pelletier EM, et al. J Med Econ. 2012;15(6):1039-50. doi: 10.3111/13696998.2012.688903. Epub 2012 May 24. J Med Econ. 2012. PMID: 22533526 Free article.

7

Oseltamivir and influenza-related complications, hospitalization and healthcare expenditure in healthy adults and children.

Gums JG, Pelletier EM, Blumentals WA. Gums JG, et al. Among authors: pelletier em. Expert Opin Pharmacother. 2008 Feb;9(2):151-61. doi: 10.1517/14656566.9.2.151. Expert Opin Pharmacother. 2008. PMID: 18201141

8

Patterns of treatment with chemotherapy and monoclonal antibodies for metastatic colorectal cancer in Western Europe.

Zhao Z, Pelletier E, Barber B, Bhosle M, Wang S, Gao S, Klingman D. Zhao Z, et al. Curr Med Res Opin. 2012 Feb;28(2):221-9. doi: 10.1185/03007995.2011.650503. Epub 2012 Jan 17. Curr Med Res Opin. 2012. PMID: 22171947

9

Direct medical costs for type 2 diabetes mellitus complications in the US commercial payer setting: a resource for economic research.

Pelletier EM, Smith PJ, Boye KS, Misurski DA, Tunis SL, Minshall ME. Pelletier EM, et al. Appl Health Econ Health Policy. 2008;6(2-3):103-12. doi: 10.1007/BF03256126. Appl Health Econ Health Policy. 2008. PMID: 19231904

10

Can adherence to antihypertensive therapy be used to promote adherence to statin therapy?

Chapman RH, Pelletier EM, Smith PJ, Roberts CS. Chapman RH, et al. Among authors: pelletier em. Patient Prefer Adherence. 2009 Nov 3;3:265-75. doi: 10.2147/ppa.s5868. Patient Prefer Adherence. 2009. PMID: 19936170 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

20 results

Search Page